What is claimed is:

1. A method of regulating cell proliferation comprising modulating the activity of a gene or polypeptide of Table 2.

2. The method of Claim 1, wherein the gene is positive for Myc binding in a chromatin immunoprecipitation (ChIP) assay.

3. The method of Claim 1, wherein the modulating is inhibiting.

4. The method of Claim 1, wherein the modulating is activating.

5. The method of Claim 1, wherein the cell proliferation is oncogenic.

6. The method of Claim 1, wherein the modulating is by a binding composition.

7. The method of Claim 6, wherein the binding composition comprises an antigen-binding site of an antibody, a soluble receptor, a nucleic acid, or a small molecule.

8. The method of Claim 7, wherein the binding composition comprises:

a) a human or humanized antibody;

b) a monoclonal antibody;

c) a polyclonal antibody;

d) an Fab fragment or an $F(ab')_2$ fragment;

e) a peptide mimetic of an antibody;

f) a detectable label; or

g) an anti-sense nucleic acid.

9. A method for the diagnosis of a proliferative condition comprising detecting or determining the expression or activity of at least one gene or polypeptide of Table 2.

10. The method of Claim 9, wherein the gene is positive for Myc binding in a ChIP assay.

11. The method of Claim 9, wherein the detecting or determining is by a binding composition comprising the antigen binding site from an antibody, a soluble receptor, or a nucleic acid.

12. The method of Claim 11, wherein the binding composition comprises:

a) a human or humanized antibody;

b) a monoclonal antibody;

c) a polyclonal antibody;

d) an Fab fragment or an $F(ab')_2$ fragment;

e) a peptide mimetic of an antibody;

f) a nucleic acid probe or nucleic acid primer; or

g) a detectable label.

13. A method of treating a subject suffering from a proliferative disorder comprising administering to the subject an effective amount of an agonist or antagonist of at least one gene or polypeptide of Table 2.

14. The method of Claim 13, wherein the gene is positive for Myc binding in a ChIP assay.

15. The method of Claim 13, wherein the proliferative disorder is oncogenic.

16. The method of Claim 13, wherein the treating is by a binding composition.

17. The method of Claim 16, wherein the binding composition comprises an antigen-binding site of an antibody, a soluble receptor, a nucleic acid, or a small molecule.

18. The method of Claim 17, wherein the binding composition comprises:

a) a human or humanized antibody;

b) a monoclonal antibody;

c) a polyclonal antibody;

d) an Fab fragment or an $F(ab')_2$ fragment;

e) a peptide mimetic of an antibody;

f) a detectable label; or

g) an anti-sense nucleic acid.